Please ensure Javascript is enabled for purposes of website accessibility

AbbVie Gets Good News on 2 Drugs from EU Committee

By Brian Orelli, PhD - Updated Jan 31, 2020 at 5:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A scientific committee recommended approvals that could expand the sales of Venclyxto and Maviret.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the agency expand its marketing authorization for two drugs from AbbVie (ABBV 0.53%): chronic lymphocytic leukemia (CLL) treatment Venclyxto and hepatitis C drug Maviret.

Venclyxto, which targets a protein called B-cell lymphoma-2, is already approved in Europe to treat CLL patients for whom previous medications have failed, with or without Roche (RHHBY 1.39%) and Biogen's Rituxan.

The new approval, if given, would allow Venclyxto to be used with Roche's Gazyva in CLL patients who haven't previously been treated, expanding the drug's potential market size. The positive opinion was based on data from the CLL14 clinical trial, which showed Venclyxto plus Gazyva helped patients live longer without their cancers progressing compared to Gazyva plus a chemotherapy called chlorambucil.

Doctor talking to a patient at a table

Image source: Getty Images.

Shorter treatment

Maviret is currently approved as a 12-week treatment regimen for patients infected with genotype 3 chronic hepatitis C virus with compensated cirrhosis of the liver, but the approval being sought would shorten the treatment to just eight weeks.

In the Expedition-8 clinical trial, Maviret, which is already approved for an 8-week regimen when treating the other 5 hepatitis C genotypes, cured 95.2% of patients with genotype 3 infections. The approval would make Maviret the only drug approved in the EU for 8-week treatment for all genotypes in patients without cirrhosis or with compensated cirrhosis. That would help Abbvie compete against Gilead Sciences' rival hepatitis C drugs Harvoni and Epclusa.

The European Commission is expected to make its final decisions on those CHMP recommendations in the first half of this year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$153.14 (0.53%) $0.80
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$42.22 (1.39%) $0.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.